How do gut microbiome-derived metabolites SCFAs LPS TMAO influence alpha-synuclein aggregation and dopaminergic neuron survival via vagal nerve signaling in Parkinson disease

PARTIALLY ADDRESSED

How do gut microbiome-derived metabolites SCFAs LPS TMAO influence alpha-synuclein aggregation and dopaminergic neuron survival via vagal nerve signaling in Parkinson disease

Priority: 0.90 Domain: neurodegeneration Hypotheses: 0

📊 Landscape Analysis

Landscape Summary: How do gut microbiome-derived metabolites SCFAs LPS TMAO influence alpha-synuclein aggregation and dopaminergic neuron survival via vagal nerve signaling in Parkinson disease is a 0.9 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.

Key Unanswered Questions

What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

How do gut microbiome-derived metabolites SCFAs LPS TMAO influence alpha-synuclein aggregation and dopaminergic neuron survival via vagal nerve signaling in Parkinson disease — INVOKE-2 (completed)

📈 Living Dashboards

0

Hypotheses

0.000

Top Score

0.000

Avg Score

1

Debates

0.84

Avg Quality

60%

Resolution

0

Mechanistic Families

Gap Resolution Progress60%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

activates (19)

UBIQUITIN→ParkinsonMITOPHAGY→ParkinsonPARKIN→Parkinson6-OHDA→ParkinsonParkinson→Oxidative Stress

▸ Show 14 more

AUTOPHAGY→ParkinsonSIRT1→ParkinsonParkinson→Immune ResponsePTEN→ParkinsonPINK1→ParkinsonNEUROINFLAMMATION→ParkinsonPARKINSON'S DISEASE→ParkinsonParkinson→Nf-ΚbParkinson→AutophagyGENES→ParkinsonParkinson→ApoptosisParkinson→MitophagyMICROGLIA→ParkinsonNRF2→Parkinson

associated with (7)

UBIQUITIN→ParkinsonParkinson→FerroptosisParkinson→Amyotrophic Lateral SclerosisCancer→ParkinsonAmyotrophic Lateral Sclerosis→Parkinson

▸ Show 2 more

Neuroinflammation→ParkinsonParkinson→Apoptosis

causes (1)

LRRK2→Parkinson

regulates (7)

PARKIN→ParkinsonAMYOTROPHIC LATERAL SCLEROSIS→ParkinsonNEURODEGENERATIVE DISORDERS→ParkinsonParkinson→Oxidative StressPINK1→Parkinson

▸ Show 2 more

Parkinson→AutophagyGENES→Parkinson

therapeutic target (16)

APOPTOSIS→ParkinsonPARKINSON'S DISEASE→ParkinsonNEURODEGENERATION→ParkinsonNEURODEGENERATIVE DISEASES→ParkinsonAUTOPHAGY→Parkinson

▸ Show 11 more

AKT→ParkinsonNRF2→ParkinsonParkinson→Oxidative StressParkinson→AutophagyParkinson→ApoptosisParkinson→Immune ResponseParkinson→ProteasomeParkinson→Blood-Brain BarrierDNA→ParkinsonGENES→ParkinsonUBIQUITIN→Parkinson

🕑 Activity Feed

✏ update on knowledge_gap by None 2026-04-25T22:15

✏ update on knowledge_gap by codex 2026-04-21T12:53

✏ update on knowledge_gap by None 2026-04-16T20:17

✏ update on knowledge_gap by None 2026-04-16T20:17

🎭 How do gut microbiome-derived metabolites SCFAs LPS TMAO inf q=0.84 2026-04-16T13:49

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

Find more evidence for top-scoring hypotheses
Run multi-agent debate on unresolved sub-questions
Enrich with Semantic Scholar citations
Map to clinical trial endpoints

← Back to All Gaps